Alzheimer's disease (AD) is a progressive neurodegenerative disease and associated with the extracellular deposits of amyloid-β peptide in hippocampus region. Metal ions like Cu, Fe and Zn are known to associate with the amyloid beta (Aβ) at high concentration and interaction of these ions with soluble and aggregated forms of Aβ peptide help in development of AD. Here we showed Cu mediated neurotoxicity in the eye tissues of transgenic Drosophila expressing human amyloid β and its rescue through a novel Cu chelator. In this context, we have synthesised and characterized the compound L 2,6-Pyridinedicarboxylic acid, 2,6-bis[2-[(4-carboxyphenyl) methylene] hydrazide] by Mass spectra (MS) and Elemental analysis (EA). The Cu chelation potential of the compound L is tested in vivo in Drosophila. Oral administration of Copper to the transgenic larvae resulted in severe degeneration in eye tissues, which was rescued by the supplementation of compound L. The levels of anti-oxidant markers like SOD and MDA were measured in compound L treated flies and found a significant rescue ( ). Further rescue of the eye degeneration phenotypes as revealed by SEM affirm the role of copper in Aβ toxicity. Hence, use of compound L, an amidoamine derivative, could be a possible therapeutic measure for Aβ induced neurotoxicity. 1. Introduction Alzheimer’s disease (AD) is the most common cause of dementia in the aging population. It is the major neurodegenerative disease of aging brain, mainly associated with the extracellular deposits of amyloid-β plaques and intracellular neurofibrillary tangles (NFT) in hippocampus region of the brain. Several studies across the globe show a strong association between loss of metal homeostasis and AD. Consequently, the research community is seriously considering the role of various bimetals and environmental metal toxins in progression and clinical outcomes of Alzheimer’s disease and other forms of neurodegenerative disorders. Metals play an important role in Alzheimer’s pathology; heavy metals such as lead, cadmium, and mercury especially are highly neurotoxic and have no other biological functions. However, nowadays, people are mainly focusing on biologically important metals such as iron (Fe), zinc (Zn), and copper (Cu) because their imbalance is related to AD. Earlier studies demonstrated that metals like copper and zinc play a critical role in amyloid beta (Aβ) aggregation and neurotoxicity [1–4]. Metal ions, mainly Cu, Fe, and Zn, have been found to colocalize with the amyloid beta (Aβ) in high concentrations, and interaction of these
References
[1]
P. Faller and C. Hureau, “Bioinorganic chemistry of copper and zinc ions coordinated to amyloid-β peptide,” Dalton Transactions, no. 7, pp. 1080–1094, 2009.
[2]
Y. H. Hung, A. I. Bush, and R. A. Cherny, “Copper in the brain and Alzheimer's disease,” Journal of Biological Inorganic Chemistry, vol. 15, pp. 61–76, 2009.
[3]
R. R. Crichton, D. T. Dexter, and R. J. Ward, “Metal based neurodegenerative diseases—from molecular mechanisms to therapeutic strategies,” Coordination Chemistry Reviews, vol. 252, no. 10-11, pp. 1189–1199, 2008.
[4]
P. S. Donnelly, Z. Xiao, and A. G. Wedd, “Copper and Alzheimer's disease,” Current Opinion in Chemical Biology, vol. 11, no. 2, pp. 128–133, 2007.
[5]
C. Hureau, “Coordination of redox active metal ions to the amyloid precursor protein and to amyloid-β peptides involved in Alzheimer disease—part 1: an overview,” Coordination Chemistry Reviews, vol. 256, no. 19-20, pp. 2164–2174, 2012.
[6]
K. J. Barnham, W. J. McKinstry, G. Multhaup et al., “Structure of the Alzheimer's disease amyloid precursor protein copper binding domain. A regulator of neuronal copper homeostasis,” The Journal of Biological Chemistry, vol. 278, no. 19, pp. 17401–17407, 2003.
[7]
L. Hesse, D. Beher, C. L. Masters, and G. Multhaup, “The βA4 amyloid precursor protein binding to copper,” FEBS Letters, vol. 349, no. 1, pp. 109–116, 1994.
[8]
A. R. White, G. Multhaup, D. Galatis et al., “Contrasting, speciesdependent modulation of copper-mediated neurotoxicity by the Alzheimer's disease amyloid precursor protein,” Journal of Neuroscience, vol. 22, no. 2, pp. 365–376, 2002.
[9]
D. G. Smith, R. Cappai, and K. J. Barnham, “The redox chemistry of the Alzheimer's disease amyloid β peptide,” Biochimica et Biophysica Acta, vol. 1768, no. 8, pp. 1976–1990, 2007.
[10]
G. Multhaup, A. Schlicksupp, L. Hesse et al., “The amyloid precursor protein of Alzheimer's disease in the reduction of copper(II) to copper(I),” Science, vol. 271, no. 5254, pp. 1406–1409, 1996.
[11]
G. Multhaup, T. Ruppert, A. Schlicksupp et al., “Reactive oxygen species and Alzheimer's disease,” Biochemical Pharmacology, vol. 54, no. 5, pp. 533–539, 1997.
[12]
D. Venarucci, V. Venarucci, A. Vallese et al., “Free radicals: important cause of pathologies refer to ageing,” Panminerva Medica, vol. 41, pp. 335–339, 1999.
[13]
R. G. Allen and M. Tresini, “Oxidative stress and gene regulation,” Free Radical Biology and Medicine, vol. 28, no. 3, pp. 463–499, 2000.
[14]
D. A. Butterfield, T. Reed, S. F. Newman, and R. Sultana, “Roles of amyloid β-peptide-associated oxidative stress and brain protein modifications in the pathogenesis of Alzheimer's disease and mild cognitive impairment,” Free Radical Biology and Medicine, vol. 43, no. 5, pp. 658–677, 2007.
[15]
C. Opazo, X. Huang, R. A. Cherny et al., “Metalloenzyme-like activity of Alzheimer's disease β-amyloid: Cu-dependent catalytic conversion of dopamine, cholesterol, and biological reducing agents to neurotoxic H2O2,” The Journal of Biological Chemistry, vol. 277, no. 43, pp. 40302–40308, 2002.
[16]
G. Eskici and P. H. Axelsen, “Copper and oxidative stress in the pathogenesis of Alzheimer’s disease,” Biochemistry, vol. 51, no. 32, pp. 6289–6311, 2012.
[17]
C. Hureau and P. Faller, “Aβ-mediated ROS production by Cu ions: structural insights, mechanisms and relevance to Alzheimer's disease,” Biochimie, vol. 91, no. 10, pp. 1212–1217, 2009.
[18]
K. J. Barnham, C. L. Masters, and A. I. Bush, “Neurodegenerative diseases and oxidative stress,” Nature Reviews Drug Discovery, vol. 3, pp. 205–214, 2004.
[19]
A. Lakatos, é. Zsigó, D. Hollender et al., “Two pyridine derivatives as potential Cu(II) and Zn(II) chelators in therapy for Alzheimer's disease,” Dalton Transactions, vol. 39, no. 5, pp. 1302–1315, 2010.
[20]
D. E. Green, M. L. Bowen, L. E. Scott et al., “In vitro studies of 3-hydroxy-4-pyridinones and their glycosylated derivatives as potential agents for Alzheimer's disease,” Dalton Transactions, vol. 39, no. 6, pp. 1604–1615, 2010.
[21]
T. Storr, M. Merkel, G. X. Song-Zhao et al., “Synthesis, characterization, and metal coordinating ability of multifunctional carbohydrate-containing compounds for Alzheimer's therapy,” Journal of the American Chemical Society, vol. 129, no. 23, pp. 7453–7463, 2007.
[22]
W. H. Wu, P. Lei, Q. Liu et al., “Sequestration of copper from β-amyloid promotes selective lysis by cyclen-hybrid cleavage agents,” The Journal of Biological Chemistry, vol. 283, no. 46, pp. 31657–31664, 2008.
[23]
C. Hureau, I. Sasaki, E. Gras, and P. Faller, “Two functions, one molecule: a metal-binding and a targeting moiety to combat Alzheimer's disease,” ChemBioChem, vol. 11, no. 7, pp. 838–953, 2010.
[24]
L. R. Perez and K. J. Franz, “Minding metals: tailoring multifunctional chelating agents for neurodegenerative disease,” Dalton Transactions, vol. 39, no. 9, pp. 2177–2187, 2010.
[25]
L. E. Scott and C. Orvig, “Medicinal inorganic chemistry approaches to passivation and removal of aberrant metal ions in disease,” Chemical Reviews, vol. 109, no. 10, pp. 4885–4910, 2009.
[26]
P. Sinha, A. k. Srivastava, and L. Mishra, “Synthesis and characterization of bis[N′-(4-carboxybenzylidene)]-pyridine-2, 6 dicarbohydrazide: colorimetric and fluorometric modulation in presence of F？ ion,” Spectrochimica Acta A, vol. 116, pp. 286–294, 2013.
[27]
A. Wolfe, G. H. Shimer Jr., and T. Meehan, “Polycyclic aromatic hydrocarbons physically intercalate into duplex regions of denatured DNA,” Biochemistry, vol. 26, no. 20, pp. 6392–6396, 1987.
[28]
M. P. Singh, M. M. K. Reddy, N. Mathur, D. K. Saxena, and D. K. Chowdhuri, “Induction of hsp70, hsp60, hsp83 and hsp26 and oxidative stress markers in benzene, toluene and xylene exposed Drosophila melanogaster: role of ROS generation,” Toxicology and Applied Pharmacology, vol. 235, no. 2, pp. 226–243, 2009.
[29]
M. Nishikimi, N. A. Rao, and K. Yagi, “The occurrence of superoxide anion in the reaction of reduced phenazine methosulfate and molecular oxygen,” Biochemical and Biophysical Research Communications, vol. 46, no. 2, pp. 849–854, 1972.
[30]
H. Ohkawa, N. Ohishi, and K. Yagi, “Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction,” Analytical Biochemistry, vol. 95, no. 2, pp. 351–358, 1979.
[31]
T. Wolff, “Preparation of Drosophila eye specimens for scanning electron microscopy,” Cold Spring Harbor Protocols, 2011.
[32]
M. Citron, “Alzheimer's disease: strategies for disease modification,” Nature Reviews Drug Discovery, vol. 9, no. 5, pp. 387–398, 2010.
[33]
G. Donmez, D. Wang, D. E. Cohen, and L. Guarente, “SIRT1 suppresses β-amyloid production by activating the α-secretase gene ADAM10,” Cell, vol. 142, no. 2, pp. 320–332, 2010.
[34]
S. No？l, F. Perez, J. T. Pedersen et al., “A new water-soluble Cu(II) chelator that retrieves Cu from Cu(amyloid-β) species, stops associated ROS production and prevents Cu(II)-induced Aβ aggregation,” Journal of Inorganic Biochemistry, vol. 117, pp. 322–325, 2012.
[35]
H. Hua, L. Münter, A. Harmeier, O. Georgiev, G. Multhaup, and W. Schaffner, “Toxicity of Alzheimer's disease-associated Aβ peptide is ameliorated in a Drosophila model by tight control of zinc and copper availability,” Biological Chemistry, vol. 392, no. 10, pp. 919–926, 2011.
[36]
J. M. McCord, B. B. Keele Jr., and I. Fridovich, “An enzyme-based theory of obligate anaerobiosis: the physiological function of superoxide dismutase,” Proceedings of the National Academy of Sciences of the United States of America, vol. 68, no. 5, pp. 1024–1027, 1971.
[37]
W. C. Orr and R. S. Sohal, “Extension of life-span by overexpression of superoxide dismutase and catalase in Drosophila melanogaster,” Science, vol. 263, no. 5150, pp. 1128–1130, 1994.
